The SFRP Family of WNT Inhibitors Function As Novel Tumor Suppressor Genes Epigenetically Silenced in Medulloblastoma
Oncogene (2010) 29, 3017–3024 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 $32.00 www.nature.com/onc SHORT COMMUNICATION The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma PN Kongkham1,2, PA Northcott1,3, SE Croul4, CA Smith1,2, MD Taylor1,3 and JT Rutka1,2 1Division of Neurosurgery, Arthur and Sonia Labatt Brain Tumor Research Centre, Toronto, Ontario, Canada; 2Program in Cell Biology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; 3Program in Developmental and Stem Cell Biology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada and 4Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada Medulloblastoma (MB) is the most common malignant signaling is crucial for normal cerebellar development, pediatric brain tumor. Dysregulation of WNT signaling as transgenic mice with reduced WNT signaling exhibit occurs in up to 20% of cases. Using a genome-wide cerebellar aplasia (McMahon and Bradley, 1990). approach, we identified the secreted frizzled-related Turcot syndrome patients with germline adenomatous protein 1, 2 and 3 (SFRP1, SFRP2 and SFRP3) family polyposis coli (APC) gene mutation and resultant of WNT inhibitors as putative tumor suppressor genes increased WNT signaling have an increased risk of silenced by promoter region methylation in MB. SFRP1, MB (Hamilton et al., 1995). Furthermore, mutations SFRP2 and SFRP3 expression increased after 5-aza-20- affecting WNT signaling members (APC, CTNNB1, deoxycytidine treatment. SFRP1, SFRP2 and SFRP3 AXIN1 and AXIN2) are seen in 15–20% of sporadic MB methylation was identified in 23.5, 3.9 and 15.7% of cases (Eberhart et al., 2000; Baeza et al., 2003; primary MB specimens, respectively, by methylation- Thompson et al., 2006; Koch et al., 2007).
[Show full text]